Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 20

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission

Robak, T., Wierzbowska, A., Błasińska-Morawiec, M., Korycka, A., Błoński, J. Z.·1999·Mediators of Inflammation
DOI 10.1080/09629359990289PMC PMC1781813
Open this paper in CoChat — free account

Abstract

We have investigated the serum concentrations of interleukin‐6 (IL‐6) and two IL‐6 family cytokines‐oncostatin M (OSM) and leukemia inhibitory factor (LIF)‐in 63 patients with B‐cell chronic lymphocytic leukemia (B‐CLL) and 17 healthy controls using the enzyme‐linked immunosorbent assay (ELISA) method. Simultaneously, we measured the serum levels of the soluble forms of two subunits of the IL‐6 receptor complex‐ligand binding glycoprotein 80 (sIL‐6R) and glycoprotein 130 (sgp130). The cytokines and receptors were evaluated in 25 untreated patients and 38 patients treated with cladribine (2‐CdA), as well as in 17 healthy controls. We have correlated the serum levels of these proteins with Rai′s clinical stage of the disease, the response to 2‐CdA treatment and some hematological parameters. We have also evaluated the correlation of the IL‐6 serum level with the concentration of OSM and IL‐6 soluble receptors. IL‐6 was measurable in 62/63 (98.4%), OSM in 20/25 (80%) of untreated and 14/38 (37.8%) of the treated patients. sIL‐6R and sgp130 were detectable in all 63 patients and LIF in none of the CLL patients. IL‐6 serum level in untreated patients was not significantly different as compared to its concentration in the control group (P > 0.05). However, in the patients treated with 2‐CdA the IL‐6 level was significantly lower (P < 0.02), and the lowest concentration was found in the patients with complete remission (CR; median 1.4 pg/ml; P < 0.02). The concentration of sIL‐6R was significantly higher in untreated (median 61.8 ng/ml) and treated (median 50.1 ng/ml) CLL patients when compared to normal persons (median 41.2 ng/ml; P = 0.04; P < 0.001, respectively). There was no difference between the sIL‐6R levels in the patients with CR and the healthy controls. In non‐responders sIL‐6R concentration was the highest and similar to its level in the untreated patients. OSM level was higher in the untreated patients (median 1.8 pg/ml) than in the normal controls (median 0.0 pg/ml; P < 0.001) and in the CR patients (median 0.0 pg/ml; P < 0.03). The serum concentration of sgp130 was similar in the untreated (median 480 pg/ml) and treated (median 470 pg/ml) patients, as well as in the healthy persons (median 420 pg/ml; P > 0.05). We have found significant positive correlation between the levels of sIL6R and the lymphocytes count in CLL patients (Ρ=0.423; P < 0.001). In addition, sIL‐6R and OSM serum concentrations correlated also with CLL Rai stage. In conclusion, the serum level of IL‐6, OSM and sIL‐6R, but not LIF and sgp130, are useful indicators of CLL activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/09629359990289

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 20

Metadata

Authors
Robak, T., Wierzbowska, A., Błasińska-Morawiec, M., Korycka, A., & Błoński, J. Z.
Venue
Mediators of Inflammation
Publisher
Wiley
Published
1999-01
Volume
8
Issue
6
Pages
277-286
ISSN
  • 0962-9351
  • 1466-1861
DOI
10.1080/09629359990289
PMC
PMC1781813
Cited by
20
References
45
Language
en
Licence
creativecommons.org/licenses/by/3.0/ (vor, 365 d)
Funders
Medical University of Łódź (502–11–499(124))

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.